DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Human secretin is an investigational drug.
There have been 18 clinical trials for Human secretin. The most recent clinical trial was a Phase 3 trial, which was initiated on September 1st 2017.
The most common disease conditions in clinical trials are Pancreatitis, Pancreatic Neoplasms, and Pancreatitis, Chronic. The leading clinical trial sponsors are ChiRhoClin, Inc., Repligen Corporation, and Massachusetts General Hospital.
There are six US patents protecting this investigational drug and forty-nine international patents.
Recent Clinical Trials for Human secretin
|Recurrent Abdominal Pain and Exocrine Pancreatic Insufficiency||ChiRhoClin, Inc.||Phase 3|
|Recurrent Abdominal Pain and Exocrine Pancreatic Insufficiency||Orlando Health, Inc.||Phase 3|
|Secretin for Acute Pancreatitis||Dartmouth-Hitchcock Medical Center||Phase 2|
Top disease conditions for Human secretin
Top clinical trial sponsors for Human secretin
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Human secretin||Start Trial||Method for use of magnetic resonance imaging to image pancreas using secretin||Wayne State University (Detroit, MI)||Start Trial|
|Human secretin||Start Trial||Method for assisting in differential diagnosis and treatment of autistic syndromes||Repligen Corporation (Waltham, MA)||Start Trial|
|Human secretin||Start Trial||Use of secretin-receptor ligands in treatment of cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD)||Pharmagene Laboratories Ltd. (Hertfordshire, GB)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Human secretin||Austria||AT295176||2017-05-19||Start Trial|
|Human secretin||Austria||AT322283||2017-05-19||Start Trial|
|Human secretin||Australia||AU4432299||2017-05-19||Start Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|